Login to Your Account



Shield Therapeutics Preps for Phase III with Anemia Drug

By Nuala Moran
Staff Writer

Friday, November 15, 2013
LONDON – Shield Therapeutics Ltd. is awaiting FDA permission for a Phase III trial of its oral iron replacement, ST10, for treating anemia in patients with chronic kidney disease (CKD) who are not on dialysis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription